Table 2.
Pathway utilization and compliance
| Variable | Pre Group (n = 276) | ERAS Group (n = 96) | p-value |
|---|---|---|---|
| Preoperative Acetaminophen, n (%) | 48 (17%) | 86 (89%) | < 0.001+ |
| Preoperative Gabapentin, n (%) | 35 (13%) | 86 (89%) | < 0.001+ |
| Scopolamine patch, n (%) | 62 (22%) | 73 (76%) | < 0.001+ |
| Nerve Block, n (%) | 51 (18%) PVB: 32 Pecs I/II: 18 |
84 (88%) PVB: 2 Pecs I/II: 81 |
< 0.001+ |
| Intraoperative TIVA, n (%) | 23 (8%) | 32 (33%) | < 0.001+ |
| Intraoperative Ondansetron, n (%) | 0 mg: 15 (5%) 4 mg: 245 (89%) 8 mg: 14 (5%) 12 mg: 0 (0%) |
0 mg: 6 (6%) 4 mg: 88 (92%) 8 mg: 1 (1%) 12 mg: 1 (1%) |
0.11+ |
| Intraoperative Dexamethasone, n (%) | 0 mg: 45 (16%) 4 mg: 100(36%) 6 mg: 69 (25%) 8 mg: 49 (18%) 10 mg: 12 (4%) |
0 mg: 2 (2%) 4 mg: 22 (23%) 6 mg: 20 (21%) 8 mg: 51 (53%) 10 mg: 1 (1%) |
< 0.001+ |
+P-values calculated from chi-square test; TIVA = total intravenous anesthesia